PubMed=8344493; DOI=10.1096/fasebj.7.10.8344493
Bhatia K.G., Goldschmidts W., Gutierrez M.I., Gaidano G., Dalla-Favera R., Magrath I.T.
Hemi- or homozygosity: a requirement for some but not other p53 mutant proteins to accumulate and exert a pathogenetic effect.
FASEB J. 7:951-956(1993)

PubMed=8402660
O'Connor P.M., Jackman J., Jondle D., Bhatia K.G., Magrath I.T., Kohn K.W.
Role of the p53 tumor suppressor gene in cell cycle arrest and radiosensitivity of Burkitt's lymphoma cell lines.
Cancer Res. 53:4776-4780(1993)

PubMed=7757991
Bae I., Fan S.-J., Bhatia K.G., Kohn K.W., Fornace A.J. Jr., O'Connor P.M.
Relationships between G1 arrest and stability of the p53 and p21Cip1/Waf1 proteins following gamma-irradiation of human lymphoma cells.
Cancer Res. 55:2387-2393(1995)

PubMed=9563901
Fan S.-J., Cherney B.W., Reinhold W.C., Rucker K., O'Connor P.M.
Disruption of p53 function in immortalized human cells does not affect survival or apoptosis after taxol or vincristine treatment.
Clin. Cancer Res. 4:1047-1054(1998)

PubMed=9787181; DOI=10.1182/blood.V92.9.3410
Sakai A., Thieblemont C., Wellmann A., Jaffe E.S., Raffeld M.
PTEN gene alterations in lymphoid neoplasms.
Blood 92:3410-3415(1998)

PubMed=10567774; DOI=10.1159/000007237
Fan S.-J., Duba D.E., O'Connor P.M.
Cellular effects of olomoucine in human lymphoma cells differing in p53 function.
Chemotherapy 45:437-445(1999)